About 50% of Asian NSCLC patients harbor EGFR sensitizing mutations, including L858R in exon 21 or E746-A750 deletion mutations (ΔE746-A750) in exon 19, which are sensitive to EGFR TKIs, such as gefitinib and erlotinib [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.